Thu, May 15, 9:38 PM (38 days ago)
**VolitionRx Limited (VNRX) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $246,385 (Q1 2024: $171,535), a 44% increase. - **Net Loss:** $5.5 million (Q1 2024: $8.5 million), a 35% decrease. - **Operating Expenses:** $5.8 million (Q1 2024: $8.6 million), a 33% decrease. - **Cash and Cash Equivalents:** $2.6 million (Q1 2024: $3.3 million). - **Cash Used in Operations:** $4.3 million (Q1 2024: $8.3 million). - **Cash Provided by Financing:** $3.7 million (Q1 2024: -$0.2 million). **Profit Margins:** - **Gross Margin:** Not explicitly stated, but implied by revenue and operating expenses. - **Operating Margin:** Negative, with operating loss of $5.5 million. **Cash Flow:** - **Operating Cash Flow:** -$4.3 million (Q1 2024: -$8.3 million). - **Investing Cash Flow:** -$0.0 million (Q1 2024: -$0.1 million). - **Financing Cash Flow:** $3.7 million (Q1 2024: -$0.2 million). **Earnings Changes:** - **Net Loss Improvement:** $3.0 million decrease in net loss compared to Q1 2024. **Quarterly Performance Discussion:** - **Revenue Growth:** Driven by increased service revenue and product sales, particularly the Nu.Q® Vet Cancer Test. - **Expense Reduction:** Significant decreases in research and development, general and administrative, and sales and marketing expenses. - **Funding:** Secured $2.4 million from equity offerings and $0.3 million from an "at-the-market" facility. **Trends and Uncertainties:** - **Positive Trends:** Revenue growth, expense reduction, and successful fundraising. - **Uncertainties:** Dependence on external financing, going concern risks, and market competition. **Future Operations Impact:** - **Strategic Focus:** Continued R&D, commercialization, and strategic partnerships. - **Financial Strategy:** Plans to use cash reserves for further R&D and commercialization, with potential additional financing through equity or debt offerings.